New study finds link between mild COVID-19 disease and certain T cell responses
3 October 2025
The study, led by researchers at the MRC Translational Immune Discovery Unit and the CAMS Oxford Institute (NDM), found that dominant T cell responses found in many individuals 4 years after infection are associated with mild COVID-19 disease, and likely play important protective roles in subsequent viral infection events.
MRC WIMM researchers receive full Professor title
1 October 2025
James Davies and Bethan Psaila have been awarded the title of Full Professor in the University’s 2025 Recognition of Distinction exercise.
Researching Iron: from Molecules to Global Health
17 September 2025
Iron deficiency is the world’s most common nutritional deficiency, affecting an estimated two billion people worldwide. The Drakesmith Group is collaborating with researchers across the University and internationally to tackle this problem from multiple angles.
Hashem Koohy receives Wellcome Discovery Award to decode T cell immunity
15 September 2025
Hashem Koohy, Associate Professor of Systems Immunology, has been awarded funding from Wellcome to develop computational strategies to decipher the underlying rules of adaptive T cell immunity.
Body-in-a-chip approach reveals how immune cells respond to heart injury
11 September 2025
Oxford scientists build a connected, ‘multi-organoid’ platform that recreates immune recruitment to the heart, opening new avenues to probe disease and test therapies.
New ‘off-the-shelf’ immunotherapy shows promise for treating high-risk childhood leukaemia
3 September 2025
Scientists at the University of Oxford, together with colleagues at Imperial College London and the University of Glasgow, have developed a new type of immunotherapy that could improve outcomes for infants and children with high-risk leukaemia.
The Kaiya Foundation to fund leukaemia research at University of Oxford
1 September 2025
The foundation has awarded one of its first major research grants to Dr Emily Neil and Professor Anindita Roy from the Childhood Leukaemia Research Group in the MRC Molecular Haematology Unit.
‘Targeted Therapies’ at Big Bang Fair 2025
20 August 2025
Earlier this year, a group of researchers from the MRC Weatherall Institute of Molecular Medicine attended the Big Bang Fair in Birmingham, showcasing medical research through a series of hands-on activities.
Platelets Shown to Store DNA in Study that could Transform Cancer Screening
15 August 2025
Study led by Psaila Group uncovers previously unknown function of platelets as DNA ‘vacuum cleaners’ in the blood, with profound implications for cancer diagnosis and prenatal screening.
Researchers create first atlas showing cell interactions in lung fibrosis
6 August 2025
New study uncovers key immune cell interaction that could explain failed lung repair in idiopathic pulmonary fibrosis (IPF)
Wellcome Discovery Award for Claus Nerlov
31 July 2025
Claus Nerlov, Professor of Stem Cell Biology, has been awarded funding from Wellcome to map the gene regulatory networks in blood cell production and seek new therapeutic targets.
Prehistoric teeth used to create historic map of infectious diseases
29 July 2025
A research project led jointly by researchers from the University of Oxford, the University of Copenhagen and University of Cambridge shows that large-scale mapping of prehistoric teeth and bones provides new knowledge of present-day infectious diseases. This may, among other things, have an impact on the development of vaccines.
New Study Links Cancer Stage to Strength of Antitumoral Immune Response in HR+ Breast Cancer
29 July 2025
The latest study from Tao Dong's Group in the MRC Translational Immune Discovery Unit has been published in Cell Reports Medicine.
Making it Personal – Engaging the public through theatre
14 July 2025
Innovative public engagement project explores the intersection of cutting-edge science and the raw honesty of the stage.
Thelior Bio: rethinking gut health from the inside out
10 July 2025
A new spinout company, formed from research conducted at the MRC Translational Immune Discovery Unit, aims to develop a new class of therapies for patients with inflammatory bowel disease.